Previous 10 | Next 10 |
Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients PR Newswire MADISON, Wis. , Dec. 9, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagn...
Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022 PR Newswire New independent clinical evidence from the pivotal TAILORx and RxPONDER trials support the role of the Oncotype ...
While some goods and services sometimes fall out of style as a result of technological innovations or other factors, that's exceedingly unlikely to happen to medical services anytime soon, not unless we develop an all-purpose drug that can cure all illnesses. Until that day, companies i...
Summary ARKK bears have failed to gain decisive selling momentum against its COVID lows. Hence, our thesis of a consolidation zone since May 2022 remains intact. We gleaned that ARKK bears could lose further momentum as we could be approaching maximum Fed hawkishness. Therefore, t...
Summary Exact Sciences demonstrated exceptional financial discipline during the third quarter, delivering robust growth with lower operating expenditure. New product launches and label expansion of existing products support the company's growth projections. Competition is incr...
Summary GH's aberrant trading pattern after its Q3 earnings release on Friday mirrors two conflicting trends arising from the company's unique market position. A new paradigm in the gene testing market is now emphasizing clearer paths to profitability, contradicting GH's spending ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/T. Schneider Shares of Cathie Wood’s flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ), are now down more than 60% year-to-date (YTD). Earlier this week,...
Image source: The Motley Fool. Exact Sciences (NASDAQ: EXAS) Q3 2022 Earnings Call Nov 03, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Exact Sciences (EXAS) Q3 2022 Earnings Call Transcript
Exact Sciences Corporation (EXAS) Q3 2022 Earnings Conference Call November 03, 2022, 17:00 ET Company Participants Megan Jones - Associate Manager, IR Kevin Conroy - Chairman & CEO Jeffrey Elliott - EVP, CFO & COO Everett Cunningham - Chief Commercia...
The following slide deck was published by Exact Sciences Corporation in conjunction with their 2022 Q3 earnings call. For further details see: Exact Sciences Corporation 2022 Q3 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...